



28 September 2001

Dockets Management Branch (HFA -305)  
Food and Drug Administration  
5630 Fishers Lane, rm. 1061  
Rockville, MD 20852

RE: Docket No. 97D-0318

Dear Sirs or Madam:

Alpha Therapeutic Corporation is providing the following comments relative to the Draft Guidance entitled, "Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products (August 2001)."

**1. Donor Screening**

Alpha feels that it would be helpful to provide guidance on the "appropriate counseling" of donors at an increased risk for CJD.

Alpha advocates that the "Recommended Questions to Identify Donors at Risk for exposure to BSE" be coordinated to coincide with SPE screening at four-month intervals.

**2. Post Donation Information**

Additional questions regarding donor travel are to be included in the screening process. As a result of these new questions, some currently qualified donors may be deferred. Language in the guidance suggests that lookbacks and BPDRs will be required as a result of this additional screening. Alpha advocates that retrospective lookbacks or BPDRs are not necessary since the current scientific evidence does not support that CJD or vCJD is transmitted by blood transfusion in humans. Additionally, implementation of new screening questions and information obtained in response to them is not an unexpected and unforeseeable event as it

8078 01 OCT 1 15 36

97D-0318

C 19

relates to previously qualified donors. Alpha advocates a prospective quarantine beginning after 31 May 2002. This approach would be similar to FDA recommendations used when implementing testing for anti-HCV.

### **3. Plasma Derivatives**

Alpha does not advocate the withdrawal of pooled plasma, intermediates, or plasma derivatives manufactured from donors with CJD or CJD risk factors, or exposure to vCJD.

### **4. Military deferrals**

It appears that the rationale for military associated deferrals is based on shipments of British beef and not exposure years. Alpha advocates a thorough review of proposed military deferral criteria and a possible revision if supported by a meaningful review of exposure years.

### **5. Clarification**

Please clarify the wording "as soon as possible" on page fifteen of the Draft Guidance. BPDR's currently must be reported within 45 days of discovery. Is this time frame acceptable?

### **6. Vegetarians**

Will FDA exclude strict vegetarians from the vCJD deferral process?

Alpha Therapeutic Corporation appreciates the opportunity to comment on this draft guidance.

Respectfully,



Paul Novikoff  
Manager, Regulatory Affairs

From: Stjei Rios / Michelle Bonillas (323)227-7284  
ALPHA THERAPEUTIC CORPORATION  
2410 LILLYVALE  
5555 VALLEY BOULEVARD  
LOS ANGELES, CA, 90032



To: Dockets Management Branch(HFA-305) (323)227-7021  
Food and Drug Administration  
5630 Fishers Lane  
Room 106  
Rockville, MD, 20852

SHIP DATE: 28SEP01  
WEIGHT: 1 LBS


Ref: P.Novikoff,6903



DELIVERY ADDRESS BARCODE (FEDEX-EDR)

FedEx **PRIORITY OVERNIGHT** IAD  
TRK # 7916 6816 6746 <sup>FORM</sup> 0201  
20852-MD-US **XA GAIA**

MON  
AA  
Deliver by:  
01OCT01



Please fold this document in half and place it in the waybill pouch affixed to your shipment so that the barcode portion of the label can be read and scanned. \*\*\*WARNING: Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number.

### Shipping Label

Schedule Courier

Find a Dropoff Location

Shipping History

Shipment Complete

Cancel Shipment

1. Use the "Print" feature from your browser to send this page to your laser or inkjet printer.
2. Fold the printed page along the horizontal line.
3. Place label in shipping label pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned.
4. To print a receipt of your shipment, please click on "Shipping History."

### Ship a New Package

Ship Inside U.S.

Ship Outside U.S.

Ship to Same Recipient

Use of this system constitutes your agreement to the service conditions in the current FedEx service Guide, available upon request.

FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$500, e.g. jewelry, precious metals, negotiable instruments and other items listed in our Service Guide. Written claims must be filed within strict time limits, see current FedEx Service Guide.